Home » Stocks » MediciNova

MediciNova, Inc. (MNOV)

Stock Price: $5.92 USD -0.26 (-4.21%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
Pre-market: $5.58 -0.34 (-5.74%) Aug 12, 4:07 AM

Stock Price Chart

Key Info

Market Cap 262.69M
Revenue (ttm) n/a
Net Income (ttm) -11.53M
Shares Out 44.37M
EPS (ttm) -0.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $5.92
Previous Close $6.18
Change ($) -0.26
Change (%) -4.21%
Day's Open 6.20
Day's Range 5.89 - 6.22
Day's Volume 351,619
52-Week Range 2.79 - 13.25

More Stats

Market Cap 262.69M
Enterprise Value 202.25M
Earnings Date (est) Oct 21, 2020
Ex-Dividend Date n/a
Shares Outstanding 44.37M
Float 41.65M
EPS (basic) -0.25
EPS (diluted) -0.26
FCF / Share -0.21
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.31M
Short Ratio 13.94
Short % of Float 5.70%
Beta 1.75
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.99
Revenue n/a
Operating Income -12.31M
Net Income -11.53M
Free Cash Flow -9.42M
Net Cash 60.44M
Net Cash / Share 1.36
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -10.05%
ROE -15.98%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$18.73*
(216.39% upside)
Low
11.0
Current: $5.92
High
25.0
Target: 18.73
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue------6.00---
Gross Profit------6.00---
Operating Income-14.03-15.59-13.03-10.88-8.88-9.24-4.05-11.78-16.19-18.06
Net Income-12.94-14.68-11.16-10.87-8.85-9.20-4.03-10.96-17.73-20.19
Shares Outstanding43.1641.1235.1432.9926.5824.0720.7016.5214.8112.41
Earnings Per Share-0.30-0.36-0.32-0.33-0.33-0.38-0.19-0.66-1.20-1.63
Operating Cash Flow-9.12-9.11-6.92-6.55-7.150.82-10.65-11.86-13.31-17.70
Capital Expenditures-0.01-0.01--0.08---0.04-0.08-0.01-0.02
Free Cash Flow-9.14-9.12-6.92-6.63-7.150.81-10.68-11.95-13.31-17.72
Cash & Equivalents63.7962.3127.9924.1222.0811.676.704.0115.0957.56
Total Debt---------43.06
Net Cash / Debt63.7962.3127.9924.1222.0811.676.704.0115.0914.50
Assets79.2177.2243.4239.8137.9127.2729.5519.5730.7972.93
Liabilities4.314.124.785.285.155.264.124.697.2948.23
Book Value74.8973.1138.6434.5332.7522.0125.4314.8823.5024.70
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name MediciNova, Inc.
Country United States
Employees 8
CEO Yuichi Iwaki

Stock Information

Ticker Symbol MNOV
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MNOV
IPO Date February 8, 2005

Description

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.